Institutional Ownership
Mersana Therapeutics Inc
CUSIP 59045L205COMMRSNQ1 2026
13D / 13G Filings
6
Schedule 13D/13G on record
Beneficial Filers
4
Distinct reporting persons
Largest Stake
7.0%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
6 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | 683 Capital Management, LLC | 13G/A | 7.0% | 351.3K | SEC |
| 2 | Jan 30, 2026 | The Vanguard Group | 13G/A | 4.2% | 210.3K | SEC |
| 3 | Jan 9, 2026 | Nextech Crossover I Gp S.A. R.L. | 13G/A | — | 913 | SEC |
| 4 | Jan 8, 2026 | Bain Capital Life Sciences Fund II, L.P. | 13D/A | — | — | SEC |
| 5 | Nov 24, 2025 | 683 Capital Management, LLC | 13G | 5.5% | 273.4K | SEC |
| 6 | Nov 13, 2025 | Bain Capital Life Sciences Fund II, L.P. | 13D/A | 4.0% | — | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ifp Advisors, Inc | 3 | $87 |